cardiac arrhythmia drug amiodarone and its primary metabolite desethylamiodarone have been proposed to function in part as thyroid hormone receptor antagonists (4) . However, these compounds bind to TRs with relatively low affinity and have complex effects on receptor function, showing both agonist and antagonist activity depending on the assay (5) . Recently, three compounds, HY-4 (6), GC-14 (7) , and DIBRT (8) , were reported to bind to TRs directly and inhibit T3 induced transcription in cultured cells. However, these compounds have relatively weak binding affinity and low potency, and therefore have not been successfully used in an animal model to date.
We are using Xenopus laevis metamorphosis as a simple and highly reproducible screen for biologically active thyroid hormone agonists and antagonists. The Xenopus system is a valuable model for thyroid hormone action for a number of reasons (1, 10) . The Xenopus thyroid hormones, thyroxine or T4, and the most potent form 3, 5, 3'-triioodthyronine, or T3, are identical in structure to the mammalian thyroid hormones (11, see Fig. 1 ). The initiation and completion of metamorphosis is dependent on thyroid hormones secreted from the developing thyroid gland (11) . Peripheral target cell concentrations of T3 are regulated through the tissue specific expression of the highly conserved Type II (D2) and Type III (D3) deiodinase enzymes (12,13). The two thyroid hormone receptor isotypes (TRα and TRβ) (14) , their heterodimer partners (RXRα, β, and γ) (15, 16) and the receptor associated co-repressors and co-activators (Neff, Lim, and Furlow, unpublished results) are structurally and functionally well conserved with their mammalian counterparts. The TRs recognize thyroid hormone response elements in native target genes that contain canonical direct repeats similar to AGGTCA separated by four base pairs (17) (18) (19) . Tadpoles readily take up thyroid hormones from their aqueous rearing solution, and respond in a dose dependent and highly stereotypic manner. Each tissue responds by on February 6, 2008 www.jbc.org Downloaded from directly and independently to the hormone based on organ culture experiments, whether the response is growth of adult cells or death of larval cells (11, 20, 21) . Thus, amphibian metamorphosis presents a unique opportunity to address important questions regarding thyroid hormone action that are common to all vertebrates.
We report here the characterization of a new thyroid hormone receptor antagonist NH-3 (9), using Xenopus laevis metamorphosis as our model system. NH-3 appears to have improved antagonistic properties over the previous compounds that may allow characterization of its activity in vivo. We present evidence that NH-3 is indeed a potent inhibitor of thyroid hormone action not only in vitro but of induced and spontaneous metamorphosis in vivo as well.
EXPERIMENTAL PROCEDURES
Chemicals-The synthesis and purification of NH-3 is described in detail elsewhere (9) . Lyophilized NH-3 was reconstituted in 100% dimethylsulfoxide (DMSO) at a concentration of 10 mM, and stored in aliquots at -20 o C until use. GC-1 was synthesized as described elsewhere (22) Two stage 57 tadpoles were added per Extra Brand Deep dish for a total of four tadpoles per group in 75 ml of 0.1xMMR. The tadpoles were bathed in 0.25 to 3 µM NH-3, 1 mM methimazole, or an appropriate amount of vehicle only (DMSO). The solutions were changed every other day and developmental stages (23) were recorded until the controls went through metamorphosis completely. At this point, NH-3 was removed and the remaining tadpoles were allowed to continue through metamorphosis in 0.1xMMR.
Tail organ culture-Tadpole tails were cultured in vitro as described previously (21) Quantitative PCR assay-Total RNA was extracted from tadpole tissues using Trizol Reagent (Invitrogen) according to manufacturer's specifications. Tissues were homogenized in Trizol with a Tekmar Tissumizer and sheared with a 21 gauge needle three times. Synthesis of cDNA was performed using pd(N) 6 (Amersham Pharmacia), Anti-RNase (Ambion, Inc.), and Superscript II (Invitrogen) according to the manufacturer's specifications. Quantitative PCR was performed using a Applied BioSystems GeneAmp 5700 Sequence Detection System, SYBR green PCR core reagents, and primers designed using Primer Express (Applied Biosystems).
Collagenase-3 was detected using primers 5'-GAAGAAGCCAGGACCTTGGAT -3'and 5'-CAAATTGCAGAGCTCCGTTGA-3'. Samples were normalized using oligonucleotides specific to RNA encoding the X. laevis ribosomal protein subunit L8, 5'-
RESULTS

NH-3 binds directly to the Xenopus TRs-
The T3 antagonist NH-3 is a derivative of the selective thyromimetic GC-1, and contains a nitrophenyl acetylene moiety attached to the 5'-position of the thyronine core (Fig. 1 ). We employed a protease protection assay in order to determine if NH-3 can bind directly to Xenopus TRs. This assay has the advantage of providing an estimate of the relative binding affinity and a means to detect conformational differences when TRs are bound to various ligands. Using elastase IV, increasing amounts of protected bands at approximately 35 kD were observed with increasing NH-3 concentrations ( Fig. 2A) . Binding of NH-3 by both xTRs is reduced from the agonists T3 and GC-1 by at least an order of magnitude (Furlow et al. submitted) . NH-3 appears to bind TRβ and TRα with a similar affinity (Fig. 2B ),
implying that this modification of GC-1 decreases isotype selectivity. Both the relative binding affinity and decreased isotype selectivity are consistent with findings using human TRs (9).
Saturating T3, GC-1, and NH-3 concentrations used in the protease protection assay revealed a distinct protected band pattern in both xTRα and β incubated with NH-3 (Fig. 2C ).
The major band in the NH-3 protected TRs corresponds to a minor band in the agonist bound receptors. This band represents a molecule approximately 1.5 kD smaller than the major agonist protected band. Thus, the 5'-phenylethynyl extension of NH-3 appears to induce a xTR conformation that is distinct from the agonist bound xTRs. xTRα or β relative to untreated controls (Fig. 3A) . In competition assays, NH-3 blocks activation by 1 nM T3 in a dose-dependent manner (Fig. 3B ). NH-3 is approximately 3 to 4-fold more potent at antagonizing 1 nM T3 activated xTRβ relative to xTRα (IC 50 100 nM vs. 380 nM respectively). This correlates well with the competitive binding assay data for human TRα and β which shows approximately 3-fold selective binding to the β-isotype (9) although this selectivity was less evident with Xenopus TRs using the protease protection assays (Fig. 2B) .
NH-3 inhibits T3 induced transcription in a transient transfection assay-
Co-activator recruitment by the TRs is inhibited by NH-3-
The molecular basis for the antagonism of T3 by NH-3 was investigated using a two-hybrid assay in HeLa cells (Fig. 4A) . T3 was 920 nM NH-3 for GRIP-1 and 870 nM for SRC-1 ( Fig. 4C and D) . xTRα showed essentially the same result, except that the inhibition curves were shifted slightly to the right as expected based on the competition curve shown in Fig. 3B (data not shown). In addition to blocking morphological changes, NH-3 also inhibits T3 induced target gene up-regulation. For example, collagenase-3 is strongly induced by T3 during metamorphosis in resorbing and remodeling tissues (24-26). NH-3 inhibits 5nM T3 induced collagenase-3 expression in a dose dependent manner that closely mirrors the effects of NH-3 on morphological changes (Fig. 7) . With NH-3 concentrations above 2µM, partial agonism of collagenase-3 expression is observed. Animals treated with high levels of NH-3 alone (2-3 µM)
NH-3 inhibits T3 induced metamorphosis-
show a low level of collagenase-3 induction that is less than 10% of the 5 nM T3-induced mRNA level. 
NH-3 inhibits spontaneous metamorphosis-
DISCUSSION
NH-3 is the first thyroid hormone receptor antagonist that effectively inhibits thyroid hormone action in an in vivo system. NH-3 was designed based on an "extension hypothesis" for development of nuclear receptor antagonists (7) . The hypothesis holds that one can predict where to modify a nuclear receptor ligand in order to place molecular extensions that should disrupt the folding of the carboxy-terminal helix 12 and therefore prevent co-activator recruitment. When bound to both Xenopus (Figs. 3 and 4) or human TRs (9), NH-3 competitively inhibits induction of a TRE containing reporter gene as well as p160 coactivator protein recruitment in a dose dependent manner. On the basis of protease protection assays performed in this study, NH-3 also clearly induces a conformational change distinct from agonist bound TRs that may reflect the predicted misfolding of helix 12 (Fig. 2C) . The difference between the major protected bands in the agonist versus antagonist bound TRs (1.5 kDa) corresponds well to the predicted size of helix 12.
Despite the effectiveness of NH-3 in vitro, its use in both basic research and in the clinic depends on its potency as an inhibitor of thyroid hormone effects in an intact organism. As a first step, we have exploited induced and spontaneous metamorphosis of the frog Xenopus laevis as a convenient bioassay for NH-3. Since the interaction of NH-3 with human and Xenopus TRs in vitro is remarkably similar, metamorphosis presents an ideal bioassay to screen for compounds with thyroid hormone antagonist activity. NH-3 is remarkably effective at inhibition of spontaneous metamorphosis as well as metamorphic changes induced by exogenously added T3.
Consistent with its lower TR isotype selectivity compared to GC-1, NH-3 inhibits most observed metamorphic responses, including tissue growth as seen in the brain and Meckel's cartilage and death of larval tissues like the internal gills and tail. Hindlimb growth is less effectively inhibited by NH-3, possibly due to its slight TRβ selectivity. NH-3 does not simply inhibit T3
uptake from the rearing media as its mode of action because it potently blocks induction of spontaneous metamorphosis by circulating endogenous thyroid hormone levels. In this case, NH-Thus, the improved design of NH-3 over previous compounds results in higher TR affinity and greater potency such that NH-3 can be used at effective but sublethal concentrations in vivo.
NH-3 shows weak partial agonist activity in both gene expression and morphological assays at concentrations >2 µM in vivo. Collagenase-3 is induced to approximately 10% of the level induced by the full agonist T3. Experiments using human TRs showed that NH-3 induces the release of the corepressor NCoR in addition to preventing coactivator binding (9) . The absence of partial agonist activity in transient transfection may result from the lack of proper chromatin assembly on transfected plasmids. Besides corepressor release, weak partial agonism could result from metabolism of NH-3 to a compound with weak agonist activity in the intact animal.
In summary, NH-3 will be a useful tool for studying the effects of reversibly blocking TR activity in a number of different animal systems. Prior to the availability of pharmacological probes, such studies have relied on TR-knockout mice that have irreversibly deprived the animal of expression of one or both TR isotypes throughout development (27) . Certainly, the utility of NH-3 in mammals will depend on various pharmacokinetic parameters such as metabolic clearance, cellular uptake, and binding to serum proteins, all of which may differ in an amphibian model. Beyond anuran metamorphosis, thyroid hormone has been implicated in a wide range of important biological processes in organisms that lack an available genetic approach. These include direct and indirect development of amphibians and fish (28) (29) (30) (31) , the control of photoperiodism in seasonally breeding birds (32) and smoltification of salmonids (33, 34) , all of which can be explored in more mechanistic detail using NH-3. 
